loading . . . Revisiting safety and refining benefit of rituximab–belimumab combination for refractory SLE B-cell depletion using rituximab is used to treat systemic lupus erythematosus (SLE),
particularly for patients whose disease is refractory to conventional immunosuppressants
(eg, mycophenolate), and ... https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913%2825%2900256-5/fulltext
